39.61

3.47% 1.33

After Hours: 39.61

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $39.61, with a volume of 1.05M. It is up +3.47% in the last 24 hours and up +21.80% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$38.28

Open:

$37.16

24h Volume:

1.05M

Relative Volume:

1.13

Market Cap:

$2.13B

Revenue:

Net Income/Loss:

$-119.95M

P/E Ratio:

-19.68

EPS:

-2.0123

Net Cash Flow:

$-95.28M

1W Performance:

+4.15%

1M Performance:

+21.80%

6M Performance:

+195.82%

1Y Performance:

+357.92%

1-Day Range:

$37.10

$40.00

1-Week Range:

$34.01

$40.65

52-Week Range:

$6.42

$40.65

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1118)

Industry

Biotechnology (624)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2025-03-26

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	39.61	2.13B	0	-119.95M	-95.28M	-2.0123
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

01:03 AM

Growth Stocks To Watch Now – April 3rd - Defense World

01:03 AM

Apr 04, 2026

A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - Yahoo Finance

Apr 04, 2026

Promising Growth Stocks To Watch Today – April 2nd - Defense World

Apr 04, 2026

Apr 03, 2026

Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com

Apr 03, 2026

Apr 02, 2026

Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks

Apr 02, 2026

Tyra Biosciences (TYRA) VP details multi-year stock option grants - Stock Titan

Apr 02, 2026

Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView

Apr 02, 2026

Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - Stock Titan

Apr 02, 2026

Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa

Apr 02, 2026

Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛

Apr 02, 2026

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 02, 2026

Growth Stocks Worth Watching – March 31st - Defense World

Apr 02, 2026

Apr 01, 2026

Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily

Apr 01, 2026

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛

Mar 31, 2026

Mar 29, 2026

Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - msn.com

Mar 29, 2026

Mar 28, 2026

Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat

Mar 28, 2026

Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - Investing.com Australia

Mar 28, 2026

Mar 27, 2026

Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com

Mar 27, 2026

Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan

Mar 27, 2026

Mar 26, 2026

Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan

Mar 26, 2026

Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada

Mar 26, 2026

Mar 25, 2026

[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com

Mar 25, 2026

Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN

Mar 25, 2026

Mar 24, 2026

Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com

Mar 24, 2026

Mar 23, 2026

Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat

Mar 23, 2026

Mar 22, 2026

Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm

Mar 22, 2026

Best Growth Stocks To Follow Today – March 20th - Defense World

Mar 22, 2026

Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World

Mar 22, 2026

Mar 21, 2026

Technical Reactions to TYRA Trends in Macro Strategies - news.stocktradersdaily.com

Mar 21, 2026

Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm

Mar 21, 2026

Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN

Mar 21, 2026

Mar 20, 2026

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com

Mar 20, 2026

Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox

Mar 20, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool

Mar 20, 2026

Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat

Mar 20, 2026

Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛

Mar 20, 2026

Mar 19, 2026

Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Mar 19, 2026

Mar 18, 2026

Forecast Cut: Can Tyra Biosciences Inc continue delivering strong returnsIPO Watch & Smart Swing Trading Techniques - baoquankhu1.vn

Mar 18, 2026

Hedge Fund Bets: Is Tyra Biosciences Inc a strong candidate for buy and holdQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Tyra Biosciences (TYRA) CFO adds 1,376 shares via employee stock plan - Stock Titan

Mar 17, 2026

Tyra Biosciences (TYRA) CEO adds 1,463 ESPP shares, holdings reach 1.36M - Stock Titan

Mar 17, 2026

Ideas Watch: Is Tyra Biosciences Incs ROE strong enoughMarket Trend Report & Smart Money Movement Tracker - baoquankhu1.vn

Mar 17, 2026